Evogene Focuses on AI Innovations in Pharma and Agriculture at Upcoming Investor Conference

Evogene Highlights Strategic Focus on AI-Driven Innovations in Pharmaceuticals and Agriculture

Evogene Ltd., a pioneering force in computational biology and chemistry, reaffirms its commitment to innovation through the upcoming presentation by President and CEO Ofer Haviv at the H.C. Wainwright 27th Annual Global Investment Conference in New York. Scheduled for September 10, 2025, at 1:00 PM ET, Haviv's presentation will spotlight the company’s proprietary generative AI technology, ChemPass AI. This advanced tech-engine is poised to revolutionize the discovery and optimization of small molecules, a vital component in both pharmaceutical and agricultural sectors. By harnessing the capabilities of ChemPass AI, Evogene aims to enhance the efficiency of small molecule development processes, thereby addressing significant challenges faced by the industry.

ChemPass AI offers a robust solution to the high costs and lengthy timelines traditionally associated with small molecule development. Evogene’s approach integrates sophisticated algorithms and data analysis to increase the success rates of drug candidates, ultimately fostering innovation in product development. The company recognizes the urgency of improving outcomes in these fields, where timely and efficient solutions can lead to faster market readiness and better responses to global health and agricultural needs. Haviv’s focus on ChemPass AI reflects Evogene’s strategic direction towards leveraging cutting-edge technology to drive competitive advantages in product development.

In addition to the presentation, Haviv will engage in one-on-one meetings with potential investors, offering a platform for deeper discussions on Evogene’s initiatives and growth trajectory. This direct interaction exemplifies the company's proactive approach to stakeholder engagement and reinforces its commitment to transparency and collaboration. Companies and investors interested in exploring partnerships or gaining insights into Evogene’s technological advancements are encouraged to connect with the Investor Relations team or utilize the conference’s online scheduling platform.

Evogene continues to solidify its position as a leader in the biotech industry by emphasizing the transformative potential of AI in enhancing pharmaceutical and agricultural innovations. For further insights into the company's strategic initiatives and technological advancements, stakeholders can visit Evogene's official website.